JP2007515383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007515383A5 JP2007515383A5 JP2006516315A JP2006516315A JP2007515383A5 JP 2007515383 A5 JP2007515383 A5 JP 2007515383A5 JP 2006516315 A JP2006516315 A JP 2006516315A JP 2006516315 A JP2006516315 A JP 2006516315A JP 2007515383 A5 JP2007515383 A5 JP 2007515383A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- hydrogen atom
- independently selected
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 106
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 67
- 125000000623 heterocyclic group Chemical group 0.000 claims description 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000005843 halogen group Chemical group 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 20
- 125000001188 haloalkyl group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical group FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 13
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 125000002837 carbocyclic group Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- -1 cyano, amino Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 150000001721 carbon Chemical class 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000006267 biphenyl group Chemical group 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 claims 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003586 protic polar solvent Substances 0.000 claims 2
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000007588 cdc25 Phosphatases Human genes 0.000 description 1
- 108010046616 cdc25 Phosphatases Proteins 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0307648A FR2856686A1 (fr) | 2003-06-25 | 2003-06-25 | Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation |
| PCT/FR2004/001578 WO2005000843A2 (fr) | 2003-06-25 | 2004-06-24 | Benzothiazole-4,7-diones et benzoxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007515383A JP2007515383A (ja) | 2007-06-14 |
| JP2007515383A5 true JP2007515383A5 (enExample) | 2007-08-16 |
Family
ID=33515381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006516315A Abandoned JP2007515383A (ja) | 2003-06-25 | 2004-06-24 | ５又は６位で置換されたベンゾチアゾール−４，７−ジオン及びベンゾオキサゾール−４，７−ジオン並びにその製造方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7335674B2 (enExample) |
| EP (1) | EP1641789A2 (enExample) |
| JP (1) | JP2007515383A (enExample) |
| KR (1) | KR20060024814A (enExample) |
| CN (1) | CN1842522A (enExample) |
| AR (1) | AR044929A1 (enExample) |
| AU (1) | AU2004251912A1 (enExample) |
| BR (1) | BRPI0411871A (enExample) |
| CA (1) | CA2530662A1 (enExample) |
| FR (1) | FR2856686A1 (enExample) |
| IL (1) | IL172774A0 (enExample) |
| MX (1) | MXPA06000217A (enExample) |
| NO (1) | NO20060124L (enExample) |
| RU (1) | RU2006101980A (enExample) |
| WO (1) | WO2005000843A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2834289B1 (fr) * | 2001-12-27 | 2004-03-19 | Sod Conseils Rech Applic | Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques |
| JP4491238B2 (ja) * | 2001-12-27 | 2010-06-30 | イプセン・ファルマ・ソシエテ・パ・アクシオンス・シンプリフィエ | ベンゾチアゾール−４，７−ジオン及びベンゾオキサゾール−４，７−ジオン誘導体、その製造方法及びその医薬用途 |
| FR2856688B1 (fr) * | 2003-06-25 | 2008-05-30 | Sod Conseils Rech Applic | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
| FR2877667B1 (fr) | 2004-11-05 | 2007-03-23 | Sod Conseils Rech Applic | Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques |
| FR2879598B1 (fr) | 2004-12-17 | 2007-03-30 | Sod Conseils Rech Applic | Inhibiteurs de phosphatases cdc25 |
| FR2945532A1 (fr) * | 2009-05-15 | 2010-11-19 | Ipsen Pharma Sas | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25 |
| CA3039919A1 (en) * | 2016-10-10 | 2018-04-19 | Development Center For Biotechnology | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2825278A1 (fr) * | 2001-05-30 | 2002-12-06 | Sod Conseils Rech Applic | Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer |
| JP4491238B2 (ja) * | 2001-12-27 | 2010-06-30 | イプセン・ファルマ・ソシエテ・パ・アクシオンス・シンプリフィエ | ベンゾチアゾール−４，７−ジオン及びベンゾオキサゾール−４，７−ジオン誘導体、その製造方法及びその医薬用途 |
-
2003
- 2003-06-25 FR FR0307648A patent/FR2856686A1/fr active Pending
-
2004
- 2004-06-24 CN CNA2004800243949A patent/CN1842522A/zh active Pending
- 2004-06-24 WO PCT/FR2004/001578 patent/WO2005000843A2/fr not_active Ceased
- 2004-06-24 RU RU2006101980/04A patent/RU2006101980A/ru not_active Application Discontinuation
- 2004-06-24 MX MXPA06000217A patent/MXPA06000217A/es not_active Application Discontinuation
- 2004-06-24 KR KR1020057024694A patent/KR20060024814A/ko not_active Withdrawn
- 2004-06-24 EP EP04767434A patent/EP1641789A2/fr not_active Ceased
- 2004-06-24 CA CA002530662A patent/CA2530662A1/fr not_active Abandoned
- 2004-06-24 BR BRPI0411871-5A patent/BRPI0411871A/pt not_active IP Right Cessation
- 2004-06-24 US US10/562,949 patent/US7335674B2/en not_active Expired - Fee Related
- 2004-06-24 JP JP2006516315A patent/JP2007515383A/ja not_active Abandoned
- 2004-06-24 AU AU2004251912A patent/AU2004251912A1/en not_active Abandoned
- 2004-06-25 AR ARP040102256A patent/AR044929A1/es not_active Application Discontinuation
-
2005
- 2005-12-22 IL IL172774A patent/IL172774A0/en unknown
-
2006
- 2006-01-09 NO NO20060124A patent/NO20060124L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510886A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2012523457A5 (enExample) | ||
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| JP2014506599A5 (enExample) | ||
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| JP2020517616A5 (enExample) | ||
| JP2014517017A5 (ja) | 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用 | |
| JP2012505871A5 (enExample) | ||
| DE60103133D1 (de) | Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren | |
| JO2644B1 (en) | Derivatives of N- (amino-aryl mixture) -H1- indole-2-carboxamide Synthesis and therapeutic use | |
| HRP20140975T1 (hr) | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze | |
| JP2016534134A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2016503799A5 (enExample) | ||
| MEP9208A (en) | Quinoline derivatives and their use as mycobacterial inhibitors | |
| JP2013531029A5 (enExample) | ||
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| JP2011037841A5 (enExample) | ||
| NZ616298A (en) | Aryl-or heteroaryl-substituted benzene compounds | |
| NO20072515L (no) | 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav | |
| JP2007514639A5 (enExample) | ||
| NZ602099A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
| JP2014508804A5 (enExample) | ||
| RU2007110629A (ru) | Ингибиторы днк-пк |